CEFEPIME HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefepime Hydrochloride, and what generic alternatives are available?
Cefepime Hydrochloride is a drug marketed by Acs Dobfar, Astral, Chartwell Rx, Hikma, Hospira Inc, Qilu, Sagent Pharms Inc, and Samson Medcl. and is included in nine NDAs.
The generic ingredient in CEFEPIME HYDROCHLORIDE is cefepime hydrochloride. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefepime Hydrochloride
A generic version of CEFEPIME HYDROCHLORIDE was approved as cefepime hydrochloride by ACS DOBFAR on March 20th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CEFEPIME HYDROCHLORIDE?
- What are the global sales for CEFEPIME HYDROCHLORIDE?
- What is Average Wholesale Price for CEFEPIME HYDROCHLORIDE?
Summary for CEFEPIME HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 114 |
| Clinical Trials: | 61 |
| Patent Applications: | 379 |
| DailyMed Link: | CEFEPIME HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CEFEPIME HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Biomedical Advanced Research and Development Authority | Phase 3 |
| Meiji Seika Pharma Co., Ltd. | Phase 3 |
| Allecra | Phase 2 |
Pharmacology for CEFEPIME HYDROCHLORIDE
| Drug Class | Cephalosporin Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for CEFEPIME HYDROCHLORIDE
US Patents and Regulatory Information for CEFEPIME HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acs Dobfar | CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 065441-001 | Mar 20, 2008 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sagent Pharms Inc | CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 091048-001 | Jan 4, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 090291-001 | Dec 21, 2010 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Astral | CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 212721-002 | Jul 21, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira Inc | CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 065369-003 | Jun 18, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
